TY - JOUR AB - Advanced‑stage gynaecological cancer represents a clinical entity with challenging surgical treatment in an effort to optimize prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) has been reported as a method potentially eligible to improve prognosis. However, no definitive conclusions have yet been made on which types of cancer and which context HIPEC may actually have a beneficial impact. The present review discusses the efficacy and safety of HIPEC as a treatment option for patients with primary/recurrent ovarian, endometrial and cervix cancer, as well as peritoneal sarcomatosis. A literature search was conducted using MeSH terms for each topic in the PubMed database and supplemented with a manual search to retrieve additional articles eligible for inclusion/fulfilling the inclusion criteria. The implementation of HIPEC appears to be beneficial in terms of survival in patients with epithelial ovarian carcinoma (EOC) following neoadjuvant chemotherapy, as well as in patients with recurrent EOC. Statistical superiority is not justified by current studies regarding other gynaecological malignancies with peritoneal dissemination. Furthermore, as regards safety, HIPEC following CRS does not appear to significantly increase the mortality and morbidity rates compared to the use of CRS alone. The rationale for using HIPEC and CRS in the treatment of ovarian cancer, particularly in the neoadjuvant setting, as well as for recurrences, is adequately evidenced, with acceptable safety and post‑operative complication rate profiles. Its current place in the multimodal strategy for patients with peritoneal metastases remains uncertain, however. Randomized clinical trials are warranted to further examine the use of HIPEC and establish the optimal regimen and temperature settings. The role of optimal cytoreduction and no residual disease, as well as the proper patient selection remain basic parameters for maximizing survival parameters. AD - 2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece 2nd Department of Obstetrics and Gynaecology, Gynaecologic Oncology Unit, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece Unit of Gynecologic Oncology, ARNAS ‘Civico‑Di Cristina‑Benfratelli’, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, I‑90121 Palermo, Italy Gynaeocologic Oncology Unit Institute Bergonie, 33076 Bordeaux, France AU - Margioula-Siarkou,Chrysoula AU - Almperis,Aristarchos AU - Papanikolaou,Alexios AU - Laganà,Antonio Simone AU - Mavromatidis,George AU - Guyon,Frederic AU - Dinas,Konstantinos AU - Petousis,Stamatios DA - 2023/05/01 DO - 10.3892/mi.2023.85 IS - 3 JO - Med Int KW - cytoreductive surgery hyperthermic intraperitoneal chemotherapy ovarian cancer endometrium cancer cervix cancer peritoneal sarcomatosis gynaecological malignancies update PY - 2023 SN - 2754-3242 2754-1304 SP - 25 ST - HIPEC for gynaecological malignancies: A last update (Review) T2 - Medicine International TI - HIPEC for gynaecological malignancies: A last update (Review) UR - https://doi.org/10.3892/mi.2023.85 VL - 3 ER -